The Bio Report

CellMax Life believes it can transform cancer diagnostics with its affordable non-invasive tests for early cancer detection. The company says with its platform it has been able to overcome the challenge of detecting rare circulating tumor cells in pre-cancer and early-stage cancer patients when the disease can be successfully treated. We spoke to Atul Sharan, co-founder and CEO of CellMax, about the challenges of liquid biopsies, how the company’s technology works, and why he thinks it has the potential to change the way cancer is diagnosed today.